AR-42
CAS No. : 935881-37-1
(Synonyms: HDAC-42; OSU-HDAC42)
| Size | Price | Stock |
|---|---|---|
| 5mg | $95 | In-stock |
| 10mg | $160 | In-stock |
| 25mg | $320 | In-stock |
| 50mg | $520 | In-stock |
| 100mg | $790 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-13265 |
| M.Wt: | 312.36 |
| Formula: | C18H20N2O3 |
| Purity: | >98 % |
| Solubility: | Ethanol : 50 mg/mL (ultrasonic);DMSO : 10 mg/mL (ultrasonic) |
AR-42 (HDAC-42) is a potent, orally bioavailable pan-HDAC inhibitor (IC50=16 nM). AR-42 induces growth inhibition, cell-cycle arrest, apoptosis, and activation of caspases-3/7. AR-42 promotes hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. AR-42 (HDAC-42) shows cytotoxicity against various human cancer cell lines.
IC50 & Target:IC50: 16 nM (HDAC)[2]
In Vitro: AR-42 (0.125-1 μM; 24 hours) inhibits cell proliferation in a dose-dependent manner, and the median IC50s for P815, C2, and BR cells are 0.65, 0.30, and 0.23 μM, respectively[3].
AR-42 (0.5 μM; 24 hours) induces cell-cycle arrest at G1 in the P815 cells and at G1/G2 in the C2 cells[3].
AR-42 (0.13-1 μM; 24 hours) causes a dose-dependent induction of apoptosis P815, C2, BR cells[3].
AR-42 (0.5-3 μM; 24 hours) induces hyperacetylation of histones H3 and H4 and α-tubulin[3].
In Vivo: AR-42 (10 mg/kg; tail vein injection; twice a week for three weeks) significantly inhibites tumor growth[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- AR-42
- Cat. No.:
- HY-13265
- Quantity:
Your information is safe with us.